PL37 belongs to Dual ENKephalinase Inhibitors (DENKI), a class of painkillers, which targets peripheral pain, of neuropathic and osteoarthritic origin in particular, by oral route as well as central pain by IV route.
The two randomised, double-blind, placebo-controlled studies comprised 168 healthy volunteers, of which 126 received PL37 by oral route.
Both the studies demonstrated good safety and tolerability of PL37.
PL37 will thus enter into Phase 2 trials.